Treatment priorities and unmet needs according to adults and adolescents with nonsegmental vitiligo in the United States [0.03%]
美国成人和青少年非节段型白癜风的治疗优先级和未满足需求
Iltefat Hamzavi,Josh Coulter,Savanna Darnell et al.
Iltefat Hamzavi et al.
Objectives: Understanding patient priorities in nonsegmental vitiligo is essential for developing therapies that address unmet needs. This study used a modified Outcome-Driven Innovation approach to quantify unmet need by...
Bianca Maria Piraccini,Giuseppe Micali,Elisabetta Fulgione et al.
Bianca Maria Piraccini et al.
Background: Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes. ...
Correction [0.03%]
改正通知书
'Oral isotretinoin plus desloratadine for acne vulgaris: an updated global meta-analysis of efficacy, safety, and patient-centered outcomes' [0.03%]
异维A酸联合左西替利嗪治疗寻常痤疮的疗效、安全性及患者转归的meta分析研究更新报告
Mishari Tariq Alrubaiaan,Reem Bajamaan,Alwaleed Mohammed Altuwaijri et al.
Mishari Tariq Alrubaiaan et al.
Background: Acne vulgaris is a common skin disorder that negatively affects adolescents' quality of life. Recent evidence suggests that combining isotretinoin with desloratadine may enhance treatment outcomes. ...
Omar Raheel,Christiaan Noot,Steven R Feldman et al.
Omar Raheel et al.
Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study [0.03%]
英国单中心纵向回顾队列研究中的中至重度银屑病患者的身体资源使用状况
Elizaveta Gribaleva,Erin Barker,Neil Hansell et al.
Elizaveta Gribaleva et al.
Background: Healthcare resource utilization (HCRU) costs in those on conventional systemics for mild-moderate psoriasis are poorly described. Objectives: ...
JAK inhibition therapy for intractable cutaneous infectious granulomatosis with unknown etiology: a case report [0.03%]
janus激酶抑制疗法治疗病因不明的难治性皮肤感染肉芽肿病1例报告
Suiting Ao,Mingjia Hu,Fanli Xu et al.
Suiting Ao et al.
Aim: To describe the clinical response to the JAK inhibition, upadacitinib, in a patient with cutaneous infectious granulomatosis. Methods: ...
Lebrikizumab off-therapy remission sustained up to 38 weeks in atopic dermatitis [0.03%]
莱布利珠单抗停药后特应性皮炎最长维持时间达38周
Jonathan I Silverberg,Thomas Bieber,Kilian Eyerich et al.
Jonathan I Silverberg et al.
Aim of the study: Lebrikizumab monotherapy demonstrated efficacy for adults and adolescents with moderate-to-severe atopic dermatitis (AD). This study aims to evaluate the relationship between lebrikizumab serum levels an...
Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years [0.03%]
提高特应性皮炎疗效标准：利布西珠单抗治疗两年可使第16周深反应者进一步改善
Eric Simpson,Tilo Biedermann,Leon Kircik et al.
Eric Simpson et al.
Background: Lebrikizumab, a high-affinity monoclonal antibody targeting interleukin-13, effectively treats moderate-to-severe atopic dermatitis (AD). Meth...
Randomized Controlled Trial
The Journal of dermatological treatment. 2026 Dec;37(1):2631233. DOI:10.1080/09546634.2026.2631233 2026
Yingying Dai,Deyu Song,Hongjie Liu et al.
Yingying Dai et al.
Purpose: Discoid lupus erythematosus (DLE) is a chronic autoimmune skin disorder that primarily affects sun-exposed areas and may lead to permanent scarring and dyspigmentation if inadequately treated. Therapeutic options...